Adam Grossman

Adam Grossman

Dr. Adam Grossman is Praedicat's Vice President of Modeling, Senior Scientist and one of Praedicat's co-founders. Adam works on the modeling team to create and implement Praedicat's risk models. Previously, Adam was an Analyst in the Emerging Risk Solutions group at RMS where he was a core member of the liability catastrophe research and development team that formed the foundation for Praedicat. Adam received his B.A.Sc. in Engineering Science from the University of Toronto, after developing flight training simulators at Defense R&D Canada. He then went on to earn his M.S. and Ph.D. in Bioengineering from Stanford University.

Research on transgenerational effects targets PCBs

Research on transgenerational effects targets PCBs 500 666 Adam Grossman

Polychlorinated biphenyls (PCBs) were phased out of use decades ago, but they remain environmentally persistent and can still be found in people’s blood. PCBs have also been shown to disrupt…

read more

Could mercury release be another unintended consequence of global warming?

Could mercury release be another unintended consequence of global warming? 500 333 Adam Grossman

Much has been made of the carbon dioxide stored in arctic ice and permafrost. The hypothesis at this time suggests that global warming will become self-reinforcing due to the increasing…

read more

Perfluorinated chemicals linked to weight gain

Perfluorinated chemicals linked to weight gain 500 175 Adam Grossman

Praedicat has been tracking perfluorinated chemicals (PFCs) since our inception. They are used in a wide range of applications, including fire retardant foams, food-contact materials, water repellents like Scotchgard, and…

read more

Evidence for a cell phone-cancer link is more tenuous than ever

Evidence for a cell phone-cancer link is more tenuous than ever 500 262 Adam Grossman

In May 2016, the U.S. National Toxicology Program (NTP) released partial and preliminary findings from a series of 2-year studies designed to test whether cell phones can cause cancer. As we…

read more

Personal exposure monitoring could be the next driver of litigation

Personal exposure monitoring could be the next driver of litigation 500 333 Adam Grossman

One of the main impediments to understanding environmental drivers of disease is having an accurate assessment of exposure.  This article shows why this barrier is beginning to vanish by detailing…

read more

Praedicat and AIG publish white paper on additive manufacturing

Praedicat and AIG publish white paper on additive manufacturing 500 333 Adam Grossman

Additive manufacturing, also known as 3D printing, has the potential to revolutionize many industries.  But like any new innovation, it creates new risks. The Praedicat approach to risk identification is…

read more

NTP prepares to classify antimony trioxide as a carcinogen

NTP prepares to classify antimony trioxide as a carcinogen 500 270 Adam Grossman

The U.S. National Toxicology Program (NTP) recently completed its draft evaluation of antimony trioxide as a human carcinogen. While the draft is still open for peer review and comment, the…

read more

Generic Drugs, Federal Preemption, and FDA Rulemaking

Generic Drugs, Federal Preemption, and FDA Rulemaking 150 150 Adam Grossman

Praedicat’s new modeling capabilities in the pharmaceutical space present both opportunities for modeling and challenges arising in the ever-changing landscape of federal pharmaceutical law and regulation.  To illustrate how we…

read more